Atelerix, a biotech company pioneering cell preservation and biological transport with its innovative hydrogel encapsulation technology, has announced that it has signed an exclusive distribution agreement with MineBio, a leading Chinese supply chain and logistics organization. Under this agreement, MineBio will serve as the sole distribution partner for Atelerix's products in China, providing solutions to the challenges of traditional cryopreservation by enabling the storage and transport of temperature-sensitive biomaterials without the need for freezing.

Atelerix’s patented hydrogels address cryologistic challenges by physically encapsulating cells, stabilizing membrane integrity, and preserving biological function during transport. This technology allows samples to remain in a ready-to-use state at ambient temperatures for up to two weeks, eliminating the costs and inefficiencies associated with the ultra-cold chain. By simplifying logistics, it reduces waste and energy consumption, streamlines shipping and handling protocols, and minimizes the loss of cell viability typically seen during cryopreservation and recovery.

The company’s solutions are suitable for a wide range of biological substances without the need for cyto-toxic or animal-derived supplements, including whole blood, primary cells, plated cell models, organoids, tissues, and viruses. The technology is adaptable and maximizes supply chain efficiency, particularly for those working with live biospecimens across research, development, and diagnostics. As research moves candidates into clinical phases, this technology enables faster, more cost-effective, and consistent pharmaceutical research—especially in highly-sensitive cell and gene workflows—offering flexibility from patient sample collection to final product delivery.

With China accounting for 37% of global clinical trials in 2024 and its biotechnology industry projected to grow at a CAGR of 19.8% between 2024 and 2030, the distribution agreement with MineBio positions Atelerix to tap into this rapidly expanding market. The collaboration marks a key milestone in Atelerix's global growth strategy, expanding product access with the support of an established life science distributor specializing in innovative solutions for cell and gene therapy, regenerative medicine, and biologics development.

“There is a growing demand for high-quality, fresh biospecimens and sophisticated in vitro models in China,” said Alastair Carrington, CEO of Atelerix. “Our exclusive distribution partnership with MineBio marks Atelerix's strategic entry into this market, coinciding with a critical time when there is an increasing global demand for advanced therapies like cell and gene therapies. MineBio's established customer base aligns perfectly with our product offerings, positioning us to meet the needs of this dynamic market. I look forward to visiting the region in the near future.”

Source: https://www.atelerix.co.uk/blogs/news/atelerix-signs-exclusive-agreement-with-minebio-to-establish-distribution-channel-for-non-cryogenic-cell-preservation-solutions-in-china